Companies Base

 
Stock Quotes for Companies Base top ^
  • Industry: Communication Equipment
  • Sector: Technology
  • Stock Style: Small Growth
  • Stock Type: Cyclical
Sign-up for lbas investment picks
  • Industry: Beverages - Wineries & Distilleries
  • Sector: Consumer Defensive
  • Stock Style: Small Core
Sign-up for sgg investment picks
  • Industry: Beverages - Wineries & Distilleries
  • Sector: Consumer Defensive
  • Stock Style: Small Core
Sign-up for 00886 investment picks
  • Industry: Gold
  • Sector: Basic Materials
  • Stock Style: Small Core
Sign-up for rbx investment picks
  • Industry: Chemicals
  • Sector: Basic Materials
  • Stock Style: Small Growth
Sign-up for 603002 investment picks
  • Industry: Shipping & Ports
  • Sector: Industrials
  • Stock Style: Small Growth
Sign-up for 200053 investment picks
  • Industry: Industrial Metals & Minerals
  • Sector: Basic Materials
  • Stock Style: Small Growth
Sign-up for bse investment picks

 
ETF Quotes for Companies Base top ^
  • Holdings: Lme Copper Future Mar13 , Lme Zinc Future Jul12 , Lme Pri Alum Futr Sep12 ,
Sign-up for dbb investment picks

 
News Articles for Companies Base top ^
Chevron Corporation (NYSE:CVX) subsidiary Chevron U.S.A. Inc. announced that it has begun commercial production of premium base oils from a newly constructed manufacturing facility at the company’s Pascagoula refinery.
Sign-up for Commercial Production Begins at Chevron’s New Premium Base Oil Plant investment picks
2014/8/18
CITIC Securities Named as an Inaugural Partner BEIJING , Aug.
Sign-up for China Finance Online Launches China's First Integrated, Web-Based Securities Trading Service Platform investment picks
MSCI Inc. (NYSE:MSCI), a leading index provider to the ETF industry worldwide for nearly 20 years, released data 1 today that highlights the continuing strength and popularity of ETFs based on MSCI indexes.
Sign-up for USD 29 Billion in Net New Assets Gathered in First 6 Months by ETFs Based on MSCI Indexes investment picks
Finda Corp Pty Ltd.
Sign-up for Location Based Technologies, Inc. GPS Trackers Chosen by Australian Warranty Network investment picks
Philips and Salesforce.com announce a strategic alliance to deliver cloud-based healthcare information technology Canada NewsWire Philips, a leading healthcare technology company and salesforce.com, the world's #1 CRM company, team up to drive industry transformation in collaborative care management between patients and healthcare professionals with new platform AMSTERDAM and SAN FRANCISCO , June 26, 2014 /CNW/ - In a move to accelerate the transformation of the healthcare industry, Royal Philips (NYSE: PHG AEX: PHIA) and salesforce.com (NYSE: CRM) today announced a strategic alliance to deliver an open, cloud-based healthcare platform, leveraging Philips' leading positions in medical technology, clinical applications and clinical informatics and salesforce.com's leadership in enterprise cloud computing, innovation and customer engagement.
Sign-up for Philips and Salesforce.com announce a strategic alliance to deliver cloud-based healthcare information technology investment picks
New Program Provides Prototypers with Daughter Boards and Services from Synopsys-Approved Third Party Providers MOUNTAIN VIEW, Calif.
Sign-up for Synopsys Announces HAPS Connect Program to Speed Creation of HAPS FPGA-Based Prototypes investment picks
Company Announcement Arzerra approved for use in EU as first-line treatment for CLL in combination with chlorambucil or bendamustine for patients ineligible for fludarabine-based therapy Approval based on Phase III data from study with ofatumumab + chlorambucil & Phase II data from study with ofatumumab and bendamustine COPENHAGEN, Denmark, July 3, 2014 (GLOBE NEWSWIRE) -- GlaxoSmithKline plc (LSE:GSK) and Genmab A/S (Copenhagen:GEN) announced today that the European Commission (EC) has granted marketing authorization for a new indication for the use of Arzerra (tm) (ofatumumab), a human monoclonal antibody against CD20, in combination with chlorambucil or bendamustine for the treatment of patients with chronic lymphocytic leukemia (CLL) who have not received prior therapy and who are not eligible for fludarabine-based therapy.
Sign-up for GSK and Genmab Receive EU Authorization for Arzerra(tm) (ofatumumab) as First-Line Treatment for Chronic Lymphocytic Leukemia (CLL) in Combination with Chlorambucil or Bendamustine for Patients Ineligible for Fludarabine-based Therapy investment picks
IRVINE, Calif., July 31, 2014 (GLOBE NEWSWIRE) -- CombiMatrix Corporation (Nasdaq:CBMX) , a molecular diagnostics company performing DNA-based testing services for developmental disorders and cancer diagnostics, today announced that its SNP-based chromosomal microarray analysis (CMA) test for miscarriage analysis, the CombiSNP™ Array for Pregnancy Loss , or products of conception, has received conditional approval from the New York Department of Health (NYDOH). This approval is for testing on fresh and formalin fixed paraffin embedded (FFPE) patient samples.
Sign-up for CombiMatrix's SNP-Based Miscarriage Analysis Test Granted Conditional Approval From New York State Department of Health investment picks

Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Companies Base
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: Companies Award  |  Next: Companies Beating